Precision oncology company Tavros Therapeutics agreed to a five-year partnership with biopharmaceutical company Vividion Therapeutics to explore four potential oncology targets using Tavros’s functional genomics discovery platform.

Under the terms of the partnership, Tavros received USD 17.5 million in an upfront cash payment. Additionally, Tavros is eligible to receive up to USD 430.5 million in preclinical, clinical, and commercial milestone payments as well as low-single-digit royalties on sales on potential programs. Vividion also has the option to develop five more targets with up to USD 482 million in future payments. 

Founded in 2020, Tavros Therapeutics aims to match biomarkers with drug combinations using its functional genomics discovery platform. It has several undisclosed drug targets in the pipeline that are focused on small-molecule inhibitors. 

Independently operated Vividion Therapeutics is a fully owned subsidiary of big pharma Bayer AG through acquisition in 2021. The company develops new drug candidates using its proprietary chemoproteomic platform to treat patients with cancer and immune diseases.